Wall Street Analysts Predict a 231.05% Upside in Trevi Therapeutics (TRVI): Here's What You Should Know

Trevi Therapeutics (TRVI) closed at $6.41, with Wall Street analysts projecting a mean price target of $21.22, implying a 231.1% upside. While acknowledging the limitations of relying solely on price targets, the article highlights a more compelling indicator: strong analyst consensus on upward earnings estimate revisions, evidenced by a 3.2% increase in the Zacks Consensus Estimate for the current year over the past 30 days. This, coupled with a Zacks Rank #2 (Buy), suggests a potential near-term upside.

Analysis

Trevi Therapeutics (TRVI) exhibits strong bullish indicators from Wall Street, although these should be interpreted with nuance. The stock, which closed at $6.41 after a 3.9% gain over the past four weeks, has a mean analyst price target of $21.22, implying a significant 231.1% potential upside. This consensus is derived from nine estimates ranging from $13.00 to $29.00. However, the analysis pivots from the potentially unreliable nature of price targets to a more empirically supported metric: earnings estimate revisions. The primary catalyst for the optimistic outlook is the positive trend in these revisions. Over the last 30 days, the Zacks Consensus Estimate for TRVI's current-year earnings has increased by 3.2%, based on one upward revision and no corresponding downward revisions. This momentum, combined with a Zacks Rank #2 (Buy), is presented as a more conclusive indicator of potential near-term stock price appreciation than the price target alone.

Key Decisions for Investors

• Investors should view the positive trend in earnings estimate revisions, specifically the 3.2% increase in the current year's Zacks Consensus Estimate, as the core bullish driver for TRVI, given its historically stronger correlation with near-term price movements.
• Treat the 231.1% implied upside from the mean price target with caution; while directionally positive, its magnitude should be seen as a sign of strong sentiment rather than a guaranteed outcome, and a starting point for deeper fundamental research.
• Given the stock's Zacks Rank #2 (Buy) and positive estimate revisions, positions should be monitored for any changes in analyst consensus or future earnings announcements, as these are the key factors underpinning the current investment thesis.